Search Results - "Poisson Ligeza, C."

Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myeloid leukaemia by Grégoire, M., Ligeza-Poisson, C., Juge-Morineau, N., Spisek, R.

“…We have recently reported in an experimental model, that treatments based on the injections of dendritic cells which had phagocytosed apoptotic bodies derived…”
Get full text

629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2) by Tougeron, D., Hautefeuille, V., Zaanan, A., Le Malicot, K., Moulin, V., Cohen, R., Lecomte, T., Aleba, A., Viaud, J., Lam, Y.H., Etienne, P.L., Mosser, L., Ramdani, M., Le Sourd, S., Poisson Ligeza, C., Goujon, G., Lepage, C., Bouche, O.

Get full text

Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD) by Zalcman, G., Mazieres, J., Greillier, L., Brosseau, S., Lantuejoul, S., Do, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., Molinier, O., Guisier, F., Urban, T., Planchard, D., Ligeza-Poisson, C., Amour, E., Morin, F., Moro-Sibilot, D., Scherpereel, A.

Get full text

1841OSecond/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD) by Zalcman, G, Mazieres, J, Greillier, L, Brosseau, S, Lantuejoul, S, Do, P, Bylicki, O, Monnet, I, Corre, R, Audigier-Valette, C, Locatelli-Sanchez, M, Molinier, O, Guisier, F, Urban, T, Planchard, D, Ligeza-Poisson, C, Amour, E, Morin, F, Moro-Sibilot, D, Scherpereel, A

“…Abstract Background The phase IIR trial IFCT-1501 (MAPS2) tested nivo or nivo+ipi in pts with relapsed MPM as second/third-line. This trial reached its primary…”
Get full text

1841O - Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD) by Zalcman, G., Mazieres, J., Greillier, L., Brosseau, S., Lantuejoul, S., Do, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., Molinier, O., Guisier, F., Urban, T., Planchard, D., Ligeza-Poisson, C., Amour, E., Morin, F., Moro-Sibilot, D., Scherpereel, A.

“…The phase IIR trial IFCT-1501 (MAPS2) tested nivo or nivo+ipi in pts with relapsed MPM as second/third-line. This trial reached its primary endpoint with 40%…”
Get full text

Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial by Zalcman, G., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., Molinier, O., Thiberville, L., Urban, T., Planchard, D., Ligeza-Poisson, C., Amour, E., Morin, F., Moro-Sibilot, D., Scherpereel, A.

Get full text

LBA58_PR Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial by Zalcman, G., Mazieres, J., Greillier, L., Lantuéjoul, Sylvie, Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., Molinier, O., Thiberville, L., Urban, T., Planchard, D., Ligeza-Poisson, C., Amour, E., Morin, F., Moro-Sibilot, D., Scherpereel, A.

Get full text

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial by Scherpereel, Arnaud, Mazieres, Julien, Greillier, Laurent, Dô, Pascal, Bylicki, Olivier, Monnet, Isabelle, Corre, Romain, Audigier-Valette, Clarisse, Locatelli-Sanchez, Myriam, Molinier, Olivier, Thiberville, Luc, Urban, Thierry, Ligeza-poisson, Catherine, Planchard, David, Amour, Elodie, Morin, Franck, Moro-Sibilot, Denis, Zalcman, Gerard

“…Abstract only LBA8507 The full, final text of this abstract will be available at abstracts.asco.org at 7:30 AM (EDT) on Monday, June 5, 2017, and in the Annual…”
Get full text

57 Efficient induction of mesothelioma-specific cytotoxic T cell responses by cross presentation of apoptotic HSP70-overexpressing mesothelioma cells by dendritic cells by Ebstein, F., Sapede, C., Royer, P.-J., Sagan, C., Ligeza-Poisson, C., Barbieux, I., Cellerin, L., Dabouis, G., Grégoire, M.

Get full text

Cytotoxic T Cell Responses against Mesothelioma by Apoptotic Cell-pulsed Dendritic Cells by Ebstein, Frederic, Sapede, Carole, Royer, Pierre-Joseph, Marcq, Marie, Ligeza-Poisson, Catherine, Barbieux, Isabelle, Cellerin, Laurent, Dabouis, Gerard, Gregoire, Marc

“…Malignant pleural mesothelioma is an uncommon tumor largely confined to the thoracic cavity, which is resistant to conventional therapies, therefore prompting…”
Get full text